Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun;3(1):13-30.
doi: 10.3355/ce.2008.009.

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Louise Profit  1 , Paul Chrisp, Carole Nadin
Affiliations

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

Louise Profit et al. Core Evid. 2008 Jun.

Abstract

Introduction: Type 2 diabetes is increasing in prevalence worldwide and is a leading cause of morbidity and mortality, mainly due to the development of complications. Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4), a new class of oral antidiabetic agents.

Aims: To evaluate the role of vildagliptin in the management of type 2 diabetes.

Evidence review: Clear evidence shows that vildagliptin improves glycemic control (measured by glycosylated hemoglobin and blood glucose levels) more than placebo in adults with type 2 diabetes, either as monotherapy or in combination with metformin. Vildagliptin is as effective as pioglitazone and rosiglitazone, and slightly less effective than metformin, although better tolerated. Further glycemic control is achieved when adding vildagliptin to metformin, pioglitazone, or glimepride. There is evidence that vildagliptin improves beta-cell function and insulin sensitivity. Vildagliptin does not appear to be associated with weight gain or with a higher risk of hypoglycemia than placebo or other commonly used oral antidiabetic agents. Economic evidence is currently lacking.

Place in therapy: Vildagliptin improves glycemic control with little if any weight gain or hypoglycemia in adult patients with type 2 diabetes when given alone or in combination with metformin, thiazolidinediones, or sulfonylureas. Since many diabetic patients require combination therapy, the complementary mechanism of action of vildagliptin and other commonly prescribed antidiabetic drugs represents an important new therapeutic option in diabetes management.

Keywords: LAF 237; dipeptidyl peptidase IV (dipeptidyl peptidase 4) inhibition; glycemic control; type 2 diabetes; vildagliptin.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Mechanism of action of current oral glucose-lowering drugs (reprinted from Stumvoll et al. 2005, with permission from Elsevier). DPP-lV, dipephidyl peptidase lV; GLP-1 glucagon-like peptide 1; NEFA, nonesterified fatty acid.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. AACE (American Association of Clinical Endocrinologists) Diabetic Guidelines. Endocrine Practice. 2002;8(Suppl 1):41–65.
    1. AACE (American Association of Clinical Endocrinologists) State of Diabetes in America. Available at: http://www.stateofdiabetes.com (accessed November 8, 2005)
    1. ACCORD Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. - PMC - PubMed
    1. ADA (American Diabetes Association) and NIDDKD (National Institute of Diabetes, Digestive and Kidney Diseases) The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742–749. - PubMed
    1. ADA (American Diabetes Association) Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl. 1):S4–S36. - PubMed